WASHINGTON (MedPage Today) -- An FDA advisory panel said the antirejection drug everolimus appears safe and effective for use in kidney transplant patients, but should be marketed with a risk mitigation plan.
Panel Recommends Everolimus in Kidney TransplantCourtesy MedPage Today Surgery Mon, 12/07/2009 - 16:41
WASHINGTON (MedPage Today) -- An FDA advisory panel said the antirejection drug everolimus appears safe and effective for use in kidney transplant patients, but should be marketed with a risk mitigation plan. More related itemsPain Patch Rejected for HIV Neuropathy
FDA Okays New Kidney Transplant Drug
Panel Endorses Novel COPD Drug
|
Popular by tags WeekMonth |
Post new comment